Verastem Announces Publication of Data for VS-5584 in Molecular Cancer Therapeutics

Verastem, Inc.,

, a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the publication of data for VS-5584 in Molecular Cancer Therapeutics. VS-5584 is a potent and selective inhibitor of the PI3K/mTOR pathway. Previous research has described a central role of this pathway in cancer stem cells. The current study details the biochemical properties and preclinical effects of this compound in multiple human tumor models. “The PI3K/mTOR signaling pathway appears critical for the survival and self-renewal of cancer stem cells,” said Jonathan Pachter, Ph.D., Verastem Vice President and Head of Research. “We have established a